Mirati Therapeutics Inc (MRTX)

5.08
NASDAQ : Health Care
Prev Close 5.09
Day Low/High 5.01 / 5.17
52 Wk Low/High 4.93 / 52.00
Avg Volume 426.90K
Exchange NASDAQ
Shares Outstanding 19.91M
Market Cap 101.33M
EPS -3.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

These stocks are setting up to trigger big breakout trades. Here's how to trade them from here.

Relative Strength Alert For Mirati Therapeutics

Relative Strength Alert For Mirati Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Mirati Therapeutics Provides Progress Update On Current Clinical Trials

Mirati Therapeutics Provides Progress Update On Current Clinical Trials

- Phase 1b data for glesatinib shows clinical activity with durable confirmed partial responses and tumor regressions in selected NSCLC patients; ongoing Phase 2 trial to optimize exposures and clinical benefit with updated formulation

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Mirati Therapeutics Becomes Oversold (MRTX)

Mirati Therapeutics Becomes Oversold (MRTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Mirati Therapeutics At $17.50, Earn 20.7% Annualized Using Options

Commit To Buy Mirati Therapeutics At $17.50, Earn 20.7% Annualized Using Options

Investors eyeing a purchase of Mirati Therapeutics Inc shares, but cautious about paying the going market price of $21.20/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $17.50 strike, which has a bid at the time of this writing of $2.30.

QIAGEN Partners To Develop Novel Companion Diagnostic In Lung Cancer

QIAGEN Partners To Develop Novel Companion Diagnostic In Lung Cancer

Collaboration with Mirati Therapeutics targets MET gene mutations to personalize treatment

Mirati Therapeutics Stock Sees Short Interest Decrease By 14%

Mirati Therapeutics Stock Sees Short Interest Decrease By 14%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 254,842 share decrease in total short interest for Mirati Therapeutics Inc , to 1,571,517, a decrease of 13.95% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Mirati Therapeutics is Now Oversold (MRTX)

Mirati Therapeutics is Now Oversold (MRTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Mirati Therapeutics At $17.50, Earn 13.4% Annualized Using Options

Commit To Buy Mirati Therapeutics At $17.50, Earn 13.4% Annualized Using Options

Investors considering a purchase of Mirati Therapeutics Inc stock, but cautious about paying the going market price of $23.88/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $17.50 strike, which has a bid at the time of this writing of $1.50.

Oversold Conditions For Mirati Therapeutics

Oversold Conditions For Mirati Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Mirati Therapeutics Enters Oversold Territory (MRTX)

Mirati Therapeutics Enters Oversold Territory (MRTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial

Mirati to Use Guardant360® Circulating Tumor DNA Diagnostic Test for Glesatinib Patient Selection and Explore the Development of Guardant360® as a Companion Diagnostic Assay

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)

Mirati Will Use FoundationOne® Genomic Profiling Assay to Identify Patients Most Likely to Benefit from Glesatinib

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)

Study Enrolling NSCLC Patients with Genetic Alterations of the MET Gene

Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients

Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients

Study Seeks to Establish a High Response Rate Among Cancer Patients with Specific Genetic Alterations that are Drivers of Tumor Growth

Interesting MRTX Put And Call Options For November 20th

Interesting MRTX Put And Call Options For November 20th

Investors in Mirati Therapeutics Inc saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRTX options chain for the new November 20th contracts and identified one put and one call contract of particular interest.

Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors

Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors

Data Presented at the 2015 European Cancer Congress Demonstrates MGCD516 is Well Tolerated with Favorable PK Profile